A newly designed uncovered biliary stent for palliation of malignant obstruction: results of a prospective study

• Published in: BMC gastroenterology 2020-06, Vol.20 (1), p.184-184, Article 184
• Main Authors: Lawrence, Christopher, Nieto, Jose, Parsons, Willis G, Roy, André, Guda, Nalini M, Steinberg, Stephen E, Hasan, Muhammad K, Bucobo, Juan Carlos, Nagula, Satish, Dey, Nicholas D, Buscaglia, Jonathan M
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Biliary tract neoplasms; Biliary Tract Surgical Procedures - instrumentation; Care and treatment; Catheters; Chemotherapy; Cholangiocarcinoma; Cholestasis; Cholestasis - etiology; Cholestasis - surgery; Consent; Decompression; Failure; Female; Gastroenterology; Humans; Implants; Innovations; Jaundice; Male; Methods; Middle Aged; Neoplasms - complications; Occlusion; Palliation; Palliative care; Palliative Care - methods; Palliative medicine; Patients; Performance evaluation; Prospective Studies; Prosthesis design; Quality of life; Self expandable metallic stent; Self Expandable Metallic Stents; Statistical analysis; Stents; Success; Treatment Outcome
• ISSN: 1471-230X; 1471-230X
• DOI: 10.1186/s12876-020-01325-9

Biliary decompression can reduce symptoms and improve quality of life in patients with malignant biliary obstruction. Endoscopically placed stents have become the standard of care for biliary drainage with the aim of improving hepatic function, relieving jaundice, and reducing adverse effects of obstruction. The purpose of this study was to evaluate the performance characteristics of a newly-designed, uncovered metal biliary stent for the palliation of malignant biliary obstruction. This post-market, prospective study included patients with biliary obstruction due to a malignant neoplasm treated with a single-type, commercially available uncovered self-expanding metal stent (SEMS). Stents were placed as clinically indicated for palliation of jaundice and to potentially facilitate neo-adjuvant chemotherapy. The main outcome measure was freedom from recurrent biliary obstruction (within the stent) requiring re-intervention within 1, 3, and 6 months of stent insertion. Secondary outcome measures included device-related adverse events and technical success of stent deployment. SEMS were placed in 113 patients (73 men; mean age, 69); a single stent was inserted in 106 patients, and 2 stents were placed in 7 patients. Forty-eight patients survived and/or completed the 6 month study protocol. Freedom from symptomatic recurrent biliary obstruction requiring re-intervention was achieved in 108 of 113 patients (95.6, 95%CI = 90.0-98.6%) at study exit for each patient. Per interval analysis yielded the absence of recurrent biliary obstruction in 99.0% of patients at 1 month (n = 99; 95%CI = 97.0-100%), 96.6% of patients at 3 months (n = 77; 95%CI = 92.7-100%), and 93.3% of patients at 6 months (n = 48; 95%CI = 86.8-99.9%). In total, only 5 patients (4.4%) were considered failures of the primary endpoint. Most of these failures (4/5) were due to stent occlusion from tumor ingrowth or overgrowth. Overall technical success rate of stent deployment was 99.2%. There were 2 cases of stent-related adverse events (1.8%). There were no cases of post-procedure stent migration, stent-related perforation, or stent-related deaths. This newly designed and marketed biliary SEMS system appears to be effective at relieving biliary obstruction and preventing re-intervention within 6 months of insertion in the overwhelming majority of patients. The device has an excellent safety profile, and associated high technical success rate during deployment. The study was registered on clinicalt